[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345136":3},{"organization":4,"outcomesModule":7,"designInfo":7,"detailedDescription":8,"studyPopulation":7,"armGroups":7,"interventions":9,"overallOfficials":16,"centralContacts":20,"locations":7,"responsibleParty":26,"collaborators":7,"id":28,"slug":7,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":7,"acronym":7,"eligibilityCriteria":32,"healthyVolunteers":29,"sex":33,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":53,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":58,"locationsCount":7},{"fullName":5,"class":6},"Ultragenyx Pharmaceutical Inc","INDUSTRY",null,"Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) and other Non-FAOD conditions, where applicable: Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies.\n\nFor full details, please visit the links provided below.",[10],{"type":11,"name":12,"description":13,"armGroupLabels":7,"otherNames":14},"DRUG","Triheptanoin","Liquid for oral (PO) or enteral tube administration",[15],"UX007",[17],{"name":18,"affiliation":5,"role":19},"Medical Director","STUDY_DIRECTOR",[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"Early Access","CONTACT","1-415-483-8800","EarlyAccess@ultragenyx.com",{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100345136",false,"NCT03773770","Expanded Access to Triheptanoin","\\- The participant must not be eligible for a UX007 clinical trial","ALL","EXPANDED_ACCESS","Expanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.",[37],"Long Chain Fatty Acid Oxidation Disorders",[39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Expanded Access","Compassionate Use","Carnitine Palmitoyltransferase Deficiency","CPT I","CPT II","Very Long Chain acyl-CoA Dehydrogenase Deficiency","VLCAD","Long Chain 3-hydroxy-acyl-CoA Dehydrogenase Deficiency","LHCAD","Trifunctional Protein Deficiency","TFP","Carnitine-acylcarnitine Translocase Deficiency","CACT","LC-FAOD","AVAILABLE","2026-04-06",{"date":56,"type":57},"2026-04-13","ACTUAL",{"name":5,"class":6}]